Acrigen Biosciences is an early-stage life science gene editing company based in Berkeley, California. We are building a pipeline of therapies to treat genetic disorders using our proprietary precision gene editing technology. Our technology utilizes novel CRISPR-Cas gene editors coupled with anti-CRISPR proteins to improve the precision, efficacy, and safety of genetic therapies. The company was co-founded in 2019 by Dr. Joseph Bondy-Denomy (Associate Professor at UCSF and discoverer of anti-CRISPR proteins) and Dr. David Rabuka (former Founder and CSO of Redwood Biosciences) with the mission of bringing precision genetic therapies to the clinic.
| Website | https://www.acrigen.com/ |
| Employees | 6 (1 on RocketReach) |
| Founded | 2019 |
| Address | 1000 Atlantic Ave Suite 104, Alameda, California 94501, US |
| Technologies |
JavaScript
,
HTML
,
Twitter
+8 more
(view full list)
|
| Industry | Biotechnology Research, Biotechnology |
| Keywords | Gene Editing, Genetic Diseases, Genetic Disorders, Crispr, Gene Therapy, Genome Engineering, Recombinant Dna, Biotechnology, Clinical Trials, Cell Therapy, Therapeutics, Pharmaceutical, Drug Discovery, Biotechnology Research, Molecular Biology, Rare Diseases, Biopharma |
| Competitors | Amgen, Genentech, Biogen, Gilead Sciences, Regeneron, Vertex Pharmaceuticals, Novartis, Lilly India, AstraZeneca, Pfizer +40 more (view full list) |
Looking for a particular Acrigen Biosciences employee's phone or email?
1 people are employed at Acrigen Biosciences.
Acrigen Biosciences is based in Alameda, California.